NCT02748616View on ClinicalTrials.gov

C. Difficile and Ursodiol

PHASE4CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

November 1, 2019

Study Completion Date

January 31, 2020

Conditions
Diarrhea
Interventions
DRUG

Ursodiol

Subjects will begin to take 300 mg Ursodiol 2 (two) weeks after Visit #1 for a total of 8 (eight) weeks.

Trial Locations (1)

10016

New York University Langone Medical Center, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT02748616 - C. Difficile and Ursodiol | Biotech Hunter | Biotech Hunter